Cellectar Biosciences Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Cellectar Biosciences şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-737.5%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-737.5%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

We Think Cellectar Biosciences (NASDAQ:CLRB) Needs To Drive Business Growth Carefully

Aug 08

Cellectar Biosciences: A Shoestring Opportunity You're About To Miss

Feb 12

Here's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation

Aug 23

Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?

Oct 05

Cellectar shares fall after mid-stage CLR 131 trial data fails to impress

Jun 04

We're Hopeful That Cellectar Biosciences (NASDAQ:CLRB) Will Use Its Cash Wisely

May 20

Cellectar Biosciences EPS beats by $0.03

May 10

Cellectar gets notification of formal grant from Australian and Mexican patent authorities

Apr 27

Cellectar commences pivotal trial of CLR 131 in a rare form bone marrow cancer

Jan 12

Cellectar Bio readies stock offering

Dec 23

We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate

Nov 30

Cellectar Biosciences EPS beats by $0.05

Nov 09

Cellectar Bio's lead asset shows encouraging action in early-stage study of pediatric tumors

Nov 05

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: CLRB şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: CLRB şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Cellectar Biosciences Piyasaya Karşı Temettü Getirisi

CLRB temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (CLRB)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.5%
Sektör Ortalaması (Biotechs)	1.7%
Analist tahmini (CLRB) (3 yıla kadar)	n/a

Önemli Temettü: CLRB şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, CLRB şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: CLRB şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: CLRB herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Güçlü temettü ödeyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/02/07 20:29
Gün Sonu Hisse Fiyatı	2025/02/07 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Cellectar Biosciences, Inc. 10 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Kumaraguru Raja	Brookline Capital Markets
Keith Markey	Griffin Securities
Ahu Demir	Ladenburg Thalmann & Company

Cellectar Biosciences Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Cellectar Biosciences Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price

Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring

Cellectar Biosciences, Inc. announced delayed 10-Q filing

Cellectar Biosciences, Inc. to Report Q3, 2024 Results on Nov 18, 2024

Cellectar Biosciences, Inc. to Present New Data from Phase 2 CLOVER -WaM Study in Oral Session at ASH 2024

Cellectar Biosciences Regains Compliance with Nasdaq Listing Rule 5250(c)(1) Regarding Filing of Form 10-Q

Cellectar Biosciences Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

Cellectar Biosciences, Inc. announced delayed 10-Q filing

No longer forecast to breakeven

Cellectar Biosciences, Inc. to Report Q2, 2024 Results on Aug 13, 2024

We Think Cellectar Biosciences (NASDAQ:CLRB) Needs To Drive Business Growth Carefully

Cellectar Biosciences, Inc. Announces Positive Results Data from its Ongoing CLover WaM Pivotal Study Evaluating Iopofosine I 131 for the Treatment of Relapsed/Refractory Waldenstrom's Macroglobulinemia

Insufficient new directors

Cellectar Biosciences, Inc. to Report Q1, 2024 Results on May 14, 2024

Cellectar Biosciences, Inc., Annual General Meeting, Jun 14, 2024

New minor risk - Market cap size

New major risk - Financial position

Price target increased by 23% to US$14.75

Cellectar Biosciences, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Cellectar Biosciences, Inc. Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

Cellectar Biosciences: A Shoestring Opportunity You're About To Miss

New major risk - Shareholder dilution

Cellectar Biosciences, Inc. Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1B Clinical Study

Cellectar Biosciences, Inc. Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient

Forecast to breakeven in 2026

Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy for Solid Tumors and Releases Promising Preclinical Data

Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia

Forecast to breakeven in 2026

New minor risk - Profitability

Cellectar Biosciences, Inc. announced that it has received $102.9 million in funding from Aigh Capital Management, LLC, ADAR1 Capital Management, LLC, Second Line Capital, LLC, Nantahala Capital Management, LLC, AuGC Partners LLC, Rosalind Advisors, Inc.

Nasdaq Grants Cellectar Biosciences an Extension to Take Action to Evidence Compliance with Nasdaq Listing Rule 5550(b), on or Before January 4, 2024

Cellectar Biosciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Cellectar Biosciences, Inc. Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom's Macroglobulinemia

Price target decreased by 7.7% to US$12.00

Cellectar Biosciences, Inc. announced that it expects to receive $102.9 million in funding from Aigh Capital Management, LLC, ADAR1 Capital Management, LLC, Second Line Capital, LLC, Nantahala Capital Management, LLC, AuGC Partners LLC, Rosalind Advisors, Inc. and other investors

Cellectar Biosciences Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1)

New major risk - Negative shareholders equity

New minor risk - Share price stability

Cellectar Biosciences, Inc. Provides an Update for Its iopofosine I 131 Clinical Program and Guidance Related to Its Proprietary Phospholipidether Drug Conjugate Platform

Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical

Cellectar Biosciences, Inc. Announces Appointment of Shane Lea as Chief Commercial Officer

Cellectar Biosciences, Inc. Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC Conference

Cellectar Biosciences, Inc. Announces Resolution of Breach of Contract and Intellectual Property Dispute

Price target decreased to US$12.60

Price target decreased to US$33.63

Cellectar Biosciences, Inc. announced that it has received $3.911327 million in funding

Cellectar Biosciences, Inc. Wins $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors

Cellectar Biosciences, Inc. Announces Publication of Data from its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-131 in Relapsed/Refractory Multiple Myeloma in Nature’s Blood Cancer Journal

Here's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation

Cellectar Biosciences GAAP EPS of -$1.22 misses by $0.19

Price target decreased to US$39.38

Cellectar announces reverse stock split

Price target increased to US$5.88

We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate

Nasdaq Grants Extension to Cellectar Biosciences Until October 31, 2022 to Regain Compliance

Cellectar Biosciences, Inc., Annual General Meeting, Jun 15, 2022

Cellectar Biosciences Appoints Jarrod Longcor as Chief Operating Officer

Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth?

Cellectar Biosciences, Inc. Presents Data from Its Ongoing Phase 2 Clover-1 Study of Iopofosine I-131 At the 63rd Ash Annual Meeting and Exposition

Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?

Cellectar Biosciences, Inc. Announces the Completion of the Part A Portion of A Safety and Tolerability Study of Iopofosine I-131 (Iopofosine) in Combination with External Beam Radiation (Ebrt) in Relapsed or Refractory Head and Neck Cancer

Price target decreased to US$5.38

High number of new directors

Cellectar Presents Data in Waldenstrom’s Macroglobulinemia in Poster At the 2021 American Society of Clinical Oncology Annual Meeting

Cellectar shares fall after mid-stage CLR 131 trial data fails to impress

We're Hopeful That Cellectar Biosciences (NASDAQ:CLRB) Will Use Its Cash Wisely

Cellectar Biosciences EPS beats by $0.03

Cellectar Biosciences, Inc. Receives Notification of Formal Grant of the Patent Titled Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles by the Eurasian, Australian and Mexican Patent Authorities

Cellectar gets notification of formal grant from Australian and Mexican patent authorities

Cellectar Biosciences, Inc. Announces Japan Patent Office Granted Patent, Titled, 'Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles'

New 90-day low: US$1.74

Cellectar Biosciences, Inc. Initiates Pivotal Trial of CLR 131 in Waldenstrom’s Macroglobulinemia

Cellectar commences pivotal trial of CLR 131 in a rare form bone marrow cancer

Cellectar Biosciences, Inc. announced that it has received $20.5065 million in funding

Cellectar Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $24.499984 million.